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ABSTRACT
Background: Tranexamic acid (TXA) reduces blood loss
by inhibiting plasminogen and preventing subsequent
fibrinolysis (stabilizing fibrin clots). Topical TXA has been
suggested for use in unicompartmental joint arthroplasty
and other procedures with residual viable cartilage.
However, the effects on human cartilage have not been
thoroughly investigated. The purpose of this study is to
determine the viability of human chondrocytes in the
setting of various concentrations of topical TXA.
Methods: 24 human osteochondral (OC) plugs were
harvested from the knee joint of a human decedent
within 36 hours of death. OC plugs underwent two
rinses with Dulbecco’s Phosphate-Buffered Saline
(DPBS) and were then exposed to three concentrations
of topical TXA (20 mg/mL, 30 mg/mL, 40 mg/mL) and
incubated at 37°C for 48 hours. Control OC plugs were
exposed to normal saline (NS). Chondrocyte viability
was evaluated with a live/dead viability/cytotoxicity
assay at days 0, 2, 4, and 6 after incubation.
Results: For days 0 and 2, viability after TXA
exposure was 70.0% ± 15.0% for all concentrations.
By day 4, viability dropped to averages below 30.0%
for all concentrations. Gross structural breakdown of
extracellular matrix surrounding the chondrocytes was
observed by day 6.
Conclusion: Commonly used concentrations of
topical TXA were shown to be chondrotoxic, and topical
application in the presence of native cartilage could

result in devastating effects on chondrocyte viability
leading to patient morbidity. Use of TXA on native
cartilage should be used with caution.
Keywords: Chondrocytes, Tranexamic acid, Cartilage,
Death

INTRODUCTION
Tranexamic acid (TXA) is a synthetic agent used to
reduce blood loss by inhibiting the breakdown of fibrin
clots. TXA reversibly binds plasminogen, inhibiting
fibrinolysis and stabilizing fibrin clots, and is used in
many surgical specialties and for traumatic hemorrhage.1
Using TXA in orthopaedic procedures has shown efficacy
in various subspecialties, including spine and trauma
procedures.2,3 It is well established that TXA has reduced
operative blood loss and post-operative transfusion
requirements in both primary total knee and hip
arthroplasty and in revision hip and knee arthroplasty.4-6
Additionally, both topical and intravenous (IV) TXA have
been shown to improve post-operative range of motion
(ROM) following primary total knee arthroplasty.7
No increase in the rate of venous thromboembolism
(VTE) with the administration of TXA has been
identified in patients with average risk for VTE.8
However, patients with a history of stroke and cardiac
stents are generally considered high risk for VTE, and
systemic/intravenous (IV) TXA is typically avoided. In
this circumstance, topical or intra-articular TXA is a safe
and equally effective alternative.9

SCIENTIFIC ARTICLES • WJO VOL. 11 • 2022

47

Though clear benefits of TXA have been
demonstrated in arthroplasty procedures, there remains
no consensus on dose or route of administration.
Moreover, questions still remain regarding TXA in other
surgical procedures involving the hip and knee joints,
including hemiarthroplasty, unicompartmental knee
arthroplasty, and even the use of topical TXA in anterior
cruciate ligament (ACL) reconstruction to reduce
post-operative hemarthrosis, promoting earlier and
overall increased ROM.10 In these circumstances, native
cartilage would be exposed to TXA.
The impact of TXA on human chondrocytes remains
unclear.11–13 In this study, the authors investigate the
effect of a range of commonly used concentrations of
topical or intra-articular TXA on human chondrocytes
ex vivo. It is hypothesized that TXA is chondrotoxic and
demonstrates both a concentration and time-dependent
effect on chondrocyte viability.

METHODS

Figure 1. Osteochondral plugs harvested from the
femur and tibia of a 56-year-old, male decedent
showing no signs of degenerative arthritis on the
articular surface (top) and placement in Fetal Bovine
Serum in preparation for washing (bottom).

Osteochondral Plug Harvest and Storage
Institutional review board (IRB) approval was obtained.
Human osteochondral (OC) plugs were harvested from
a decedent obtained through a local donor services
company. The decedent was a 56-year-old male with no
documented surgical history, no history of osteoarthritis,
rheumatoid arthritis, or other inflammatory arthropathy
that would affect cartilage. OC plugs were harvested

Figure 2. Visual flow-chart of TXA/NS treatment of osteochondral plugs summarizing the
methodology used for this study. Plugs are obtained using OATS, transferred to FBS, washed,
placed in cell media for 2 hours, and exposed to normal saline for 1-minute lavage or a 48-hour
soak in tranexamic acid dissolved in cell media.
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within 36 hours of death. Harvest and preparation are
modeled after Campbell et al.7 Plugs were obtained
from the articular surface of the distal femur and
proximal tibia using the osteoarticular allograft transfer
system (OATS) (Arthrex, Naples, FL). Harvested knee
articular cartilage was visually confirmed to be intact
and healthy appearing, with any regions devoid of
intact articular cartilage or signs of damage discarded
(Figure 1). 48 OC plugs were collected and transferred
into fetal bovine serum (FBS) solution followed by a
wash and rescue period (Figure 2).
OC plugs were washed with DPBS before being
stored in standard nutrient mixture made from
Dulbecco’s Modified Eagle Medium/F-12 (DMEM/F12)
1:1 media with 10.0% FBS, 1.0% penicillin/streptomycin
(P/S), and 1.0% Fungizone at 37° C for 2 hours prior
to treatment. All wash and storage materials were
purchased from VWR Life Sciences (Sanburn, NY).
Tranexamic Acid Exposure and Control
OC plugs were exposed to either 0.9% normal saline
(NS) or to TXA (Pharmaceutical grade obtained from
Sigma Aldrich [St. Louis, Missouri]) at 20 mg/mL, 30
mg/mL, and 40 mg/mL (500 mg, 750 mg, and 1000
mg diluted in 25 mL cell media). This was performed by
either a 1-minute lavage treatment with NS or a 48-hour
soak treatment of TXA. Both groups of OC plugs were
kept in cell media for the remainder of treatment. Three
OC plugs were used for each group, treatment, and day
(NS x 3 plugs x 4 days = 12; TXA x 3 concentrations x 3
plugs x 4 days = 36).
Live/Dead Cell Viability/Toxicity Assay
The protocol for the live/dead assay follows those
of Cooperstein et al.14 Briefly, a combined live/dead
solution was made by adding 1µL of calcein AM (1mM
stock solution), and 1 µL of ethidium homodimer-1
(2 mM) to 1 mL of DPBS. OC plugs were maintained in
cell media, changed every 24 hours, and removed for
viability tests at specified times after exposure: days 0,
2, 4, and 6. Plugs were rinsed and all bone removed. The
remaining chondral region for each plug was sectioned
into approximately nine segments. Cell media was
then replaced with a working live/dead solution. The
chondral segments were incubated at 37.0°C and 5.0%
CO2 with live/dead solution for 60 minutes and then
rinsed with sterile DPBS prior to imaging.
Fluorescent images were obtained with a
Nikon Eclipse TS200F inverted microscope at 10X
magnification with an epifluorescence attachment
(Nikon Instruments, Melville, NY) and a SPOT Insight
color mosaic digital camera (Diagnostic Instruments,
Sterling Heights, MI). After imaging (~27 images across
nine pieces from each plug), cells were analyzed and
counted using FIJI (Image J Software), following a
previously established protocol.15
Statistical Analysis
TXA dose, evaluation time, and the interaction of dose
and time were evaluated in relation to the proportion of

Figure 3. Percent live cells of 0 days (blue), 2 days
(orange), 4 days (grey), and 6 days (yellow) after
treatment of NS. The red line is set to 70% viability,
below which treatments are considered cytotoxic. **
indicates p-values are <0.05 using Tukey-Kramer test.

Figure 4. Live (left), dead (middle), and merged (right)
images of live/dead stain of osteochondral plugs at day
0 after treatment of NS, 20 mg/mL TXA, 30 mg/mL
TXA, and 40 mg/mL TXA. Scale bar = 300 µm.
live chondrocytes (log-transformed to meet normality
assumptions) using analysis of variance (ANOVA).
Cytotoxicity was defined as the presence of less than
70.0% living chondrocytes.16 Saline treatment evaluated
at the equivalent times served as the normal control.
An unstructured variance (allowing heterogeneous
variance) provided the best fit to the data. Multiple
comparisons were considered using the Tukey-Kramer
method. All analyses were conducted using SAS v. 9.4
(Cary, N.C.).
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Figure 5. Percent live cells of 0 days (blue), 2 days (orange), 4 days (grey),
and 6 days (yellow) after treatment of 20 mg/mL TXA, 30 mg/mL TXA, and
40 mg/mL TXA. The red line is set to 70% viability, below which treatments
are considered cytotoxic. ** indicates p-values are <0.05 using Tukey
Kramer test.

Figure 6. Live (left), dead (middle), and merged (right)
images of live/dead stain of osteochondral plugs at
0 days, 2 days, 4 days, and 6 days after treatment of
30 mg/mL TXA. The indiscriminate green staining is
likely a result of calcein AM’s interaction with cytosolic
esterases that can leak out of cells as they die. Scale bar
= 300 µm.
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Results
Chondrocytes exposed to NS used as a control
remained viable through day 6 (Figure 3). Immediately,
at day 0, fluorescent microscopy showed more viable
chondrocytes exposed to NS compared to TXA at
20 mg/mL, 30 mg/L, and 40 mg/ml concentrations
(Figure 4). Chondrocytes exposed to all concentrations
of TXA demonstrated decreasing viability, ranging
between 70.2% to 78.6% on day 0 to 14.2% to 22.5%
on day 6 (Figure 5). TXA resulted in near cytotoxic
levels of viability at day 0 for all TXA concentrations.
At day 2, all levels became cytotoxic. Beginning at day
4, viability decreased drastically, continuing at 6 days
after exposure. Figure 6 shows a representative sample
from 30 mg/ml concentrations of TXA. Table 1 details
percent viability of chondrocytes after exposure to TXA
at days 0, 2, 4, and 6 at all concentrations.
Type I and Type III ANOVA analyses indicate that
time, dose, and the interaction of treatment and time
were significant, suggesting chondrocyte viability is
dependent on increasing dose and time (Table 2).
The GLM procedure of least squares mean showed
that exposure of chondrocytes to 20 mg/mL, 30 mg/
mL, and 40 mg/mL of TXA significantly differed from
normal saline at all times. Further analysis of TXA
concentration effects within individual days showed
that chondrocyte viability versus concentration was not
significantly different.
Qualitative results during dissection demonstrated
degradation of OC plugs over time with exposure to
TXA. By day 4 and day 6 after treatment, OC plugs
were increasingly difficult to dissect following the
same protocols established by previous experiments.
Furthermore, initial exposure to TXA rapidly dropped

Table 1. % viability of chondrocytes (mean & standard deviation [SD]) by days following exposure (0, 2, 4, and 6)
and % concentration of TXA.
Days Following Exposure to TXA

0

2

4

6

% Concentration of TXA (mg/mL)

20

30

40

20

30

40

20

30

40

20

30

40

% Viability of Chondrocytes
(mean)

70.2

79.0

78.6

69.2

67.4

67.5

14.9

21.4

24.8

14.2

22.5

22.4

% Viability of Chondrocytes (SD)

5.6

13.6

11.6

15.0

14.1

17.3

12.1

16.3

15.2

13.2

9.9

8.6

Table 2. ANOVA type I (top) and III (bottom) results comparing TXA effects of time and dose on chondrocyte
viability. All p-values are <0.0001 indicative that exposure to TXA observed over time, increasing concentrations
of TXA, and the effects of time and concentration together were significant. Degrees of freedom (DF). Sum of
squares (SS)
Type I ANOVA
Source

DF

SS

Mean Square

F Value

P>F

TXA effects of time

3

49.72

16.57

61.61

<0.001

TXA effects of dose

3

37.08

12.36

45.95

<0.001

TXA effects of time *
dose

9

39.23

4.36

16.20

<0.001

Source

DF

SS

Mean Square

F Value

P>F

TXA effects of time

3

71.20

23.73

88.21

<0.001

TXA effects of dose

3

37.08

12.36

45.95

<0.001

TXA effects of time *
dose

9

39.23

4.36

16.20

<0.001

Type III ANOVA

the cell media’s pH, as indicated by a color change in
the cell media from red to yellow (due to the presence
of phenol red in the cell media). Although OC plugs
were rinsed between every cell media change, plugs
exposed to TXA required a cell media change every 24
hours due to decreasing pH. These observations were
not found in samples exposed to NS treatment.

DISCUSSION
Ex vivo human chondrocytes exposed to common
concentrations of topical TXA showed considerable
cell death in comparison to controls. Chondrocytes
were viable ex vivo following NS wash treatment at
6 days after exposure. There was a natural decline in
the NS group, demonstrating cell death that naturally
occurs to ex vivo chondrocytes that remain in cell
media. However, a large percentage of the NS OC plugs
remained viable. The results of this study contrast with
other studies that have also investigated chondrocyte
viability after exposure to TXA; however, this is because
there were different post-exposure methodologies and

TXA concentrations investigated in this study that were
not evaluated by others.12,13 More specifically, this study
increased post-exposure evaluation time to account
for delayed cell death, increased time of exposure to
TXA to simulate the potential effects that plasminogen
binding may have on TXA in a surgical setting, and
evaluated TXA concentrations above 25 mg/mL, a
typical concentration used by surgeons intraoperatively.
Tuttle et al13 evaluated bovine and murine
chondrocyte viability immediately after exposure
(day 0) to 25 mg/mL of TXA for 48 hours and found
that viability was similar to that of controls. We
suggested that there could be a delayed cell death
after TXA exposure exceeding 48 hours; therefore,
this study extended the observation of cells to 6 days.
Other studies have shown the half-life of TXA to be
approximately 2.3 hours17; however, these findings were
the free form of TXA and not bound to plasminogen,
which alters the kinematics and half-life of TXA. Ahlberg
et al18 evaluated the diffusion of TXA from the knee
joint, showing the pharmacokinetics of TXA in joint fluid
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was similar to that of serum. TXA was administered
and concentration was measured prior to any surgical
insult of the knee joint, inferring the TXA was acting in
its solute or unbound form. Proteins in their unbound
form demonstrate different pharmacokinetics than their
bound counterparts; protein and protein-bound solutes
diffuse from a joint at a much slower rate.19,20 Wallis et
al21 demonstrated that the effusion times of radiolabeled
protein (albumin) had an average elimination half-life
of ~32 hours. The authors believe that once TXA binds
to plasminogen in the joint, it behaves differently from
its unbound state. After surgical insult, plasminogen
is exposed, readily binding TXA, putting TXA in its
bound form and delaying its diffusion from the joint.
Sangasoongsong et al22 confirmed this in their study
evaluating TXA concentrations in the joint after TKA,
measured through a drain intraoperatively placed.
Diluted concentrations of TXA were placed in the
joint along with a drain, which was clamped. The
drains were unclamped at varying time points postoperatively and concentrations of TXA were measured.
The concentrations were variable throughout patients,
but no concentration change was observed up to 12
hours. In fact, although not statistically significant,
TXA levels at 12 hours compared to 2 hours nearly
doubled. Given these findings, we believe that proteinbound TXA, which would be expected in the setting of
postoperative hemarthrosis, would have a half-life in
the joint for at least 12 hours. Therefore, the authors of
this study exposed human chondrocytes to TXA for 48
hours to demonstrate a more likely clinical scenario of
TXA exposure duration to chondrocytes.
Extended observation demonstrated delayed-cell
death when exposed to TXA, demonstrating a likely
occurrence if native cartilage were exposed. There was
a significant decline in human chondrocyte viability at
4 days and 6 days, suggesting delayed cell death after
exposure to TXA. Parker et al12 investigated the viability
of human chondrocytes in vitro after exposure to
concentrations of 10 mg/mL to 20 mg/mL of TXA
for only 3 hours on a 3D human chondrocyte laden
gelatin-methacryloyl hydrogel model. They found no
significant differences in cell viability compared to
controls.12 The basis for a 3-hour exposure was a study
by Ahlberg et al.18
This study is comparable to a recent study by
Goderecci et al11, which evaluated in vitro human
chondrocytes exposed to 20 mg/mL, 50 mg/mL, 70
mg/mL, and 100 mg/mL of TXA for 10 minutes, 24
hours, or 48 hours. Like the study by Parker et al12,
Goderecci et al11 found that short-term exposure to TXA
(10 minutes) was not different in viability from controls,
and no appreciable cytotoxicity was seen under 100
mg/mL. Alternatively, with 24- or 48-hour exposure,
appreciable cytotoxicity was observed as soon as 1-day
post-exposure at concentrations over 20 mg/mL. This
study, which uses an ex vivo model and concentrations
of 30 mg/mL and 40 mg/mL, supports the finding that
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long exposure times and high concentrations have an
adverse effect on viable chondrocytes. Additionally,
secondary to decreasing pH, OC plugs exposed to TXA
required a cell media change every 24 hours, which was
not required in OC plugs exposed to NS. This acidity
likely contributed to the decline in cell viability found
in OC plugs exposed to TXA. This suggests that native
chondrocytes, as seen in hemi-arthroplasty, ligament
reconstruction, or arthroscopy would be affected. We
were unable to find any similar findings in the literature
regarding a lowering of pH with persistent exposure to
TXA; we feel that this should be a future area of study.
Topical TXA concentrations also varied widely
in studies assessing the impact of TXA. There is no
definitive dose of TXA in arthroplasty, and protocols vary
greatly for intra-articular or topical administration of
TXA, from 250 mg to 3 grams, while actual intra-articular
concentrations are also variable and inconsistent, varying
from 15 mg/mL to 100 mg/mL. Topical application is also
variable with TXA being administered after TXA implants
either locally by periarticular injection or injected into
a drain after the fascial layer is closed. Picetti et al23
found that 10 mg/mL to 15 mg/mL of TXA resulted
in substantial inhibition of fibrinolysis, but efficacy
regarding operative blood loss and postoperative
transfusion was not evaluated. The authors feel that
obtaining such a specific concentration in an operative
setting within the joint would be very difficult, given
the differences of joint volume in the setting of postoperative hemarthrosis among patients. Panteli et al24
found that a dose of more than 2 grams of TXA trended
toward decreased post-operative transfusion rates. This
suggests that a higher concentration may be needed
for clinical effectiveness, although when using topical
or intra-articular TXA in the setting of post-operative
hemarthrosis, it is difficult to predict final concentration
and would be highly variable among patients.
From these results, it can be inferred that doses of
intra-articular and topical TXA commonly used may
be toxic to native chondrocytes in procedures such
as hemiarthroplasty, ligament reconstruction, and
arthroscopic procedures. Because it is paramount to
preserve and protect cartilage during these procedures,
the authors caution against using TXA in the setting
of native cartilage. Further investigation of the
pharmacokinetics of bound TXA-plasminogen within
the joint and the effects of TXA-plasminogen exposure
to chondrocytes at various concentrations would be
beneficial.
This article is not without some limitations. TXA
concentrations were tested on ex-vivo cartilage plugs.
While conclusions may be drawn for cartilage
in-vivo, this information needs to be taken with caution.
Additionally, all chondrocyte plugs were harvested from
one donor. Though there was only one donor, there
were numerous healthy OC plugs obtained that had
living cartilage for both arms of the experiment. Future
studies evaluating numerous donors to obtain more OC

plugs would broaden the understanding of this topic.
Nevertheless, this study provides a good framework and
baseline for chondrocyte response to TXA, suggesting
TXA may be toxic to native cartilage.
Commonly used concentrations of topical TXA were
shown to be chondrotoxic to chondrocytes in the ex
vivo setting, and topical application in the presence
of native cartilage could result in devastating effects
on chondrocyte viability, leading to patient morbidity.
Further studies are still needed to evaluate the true
pharmacokinetics of bound TXA within an intraarticular space and the effect of TXA on chondrocytes
in an in vivo setting, but given the current findings, use
of TXA on native cartilage should be taken with caution.
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